Literature DB >> 18723016

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

Marios Politis1, Paola Piccini, Nicola Pavese, Seong-Beom Koh, David J Brooks.   

Abstract

A mild to moderate reduction in dopamine, noradrenaline and serotonin levels alongside a progressive loss of hypocretin cells and melanin hormone concentrating cells has been reported in the hypothalamus of PD at postmortem. Hypothalamic uptake of (18)F-dopa PET, an in vivo marker of dysfunction of monoaminergic neurons, is also significantly reduced in these patients. These data indicate a general impairment of hypothalamic function in PD. Dopamine receptors play an important role in the regulation of hypothalamic pathways. To date, possible changes in hypothalamic D(2) receptor availability have not been investigated in PD. The objective in this study was to assess dopamine D(2) receptor availability in hypothalamus of patients with idiopathic Parkinson's disease (PD) using positron emission tomography (PET) with (11)C-raclopride (RAC). We evaluated D(2) binding in RAC PET images of 14 PD patients using both region of interest (ROI) analysis and a voxel based approach. ROIs for the hypothalamus were traced on the subject's MRI co-registered to the PET image. (11)C-raclopride binding potentials (BP) for hypothalamus were obtained by applying ROIs onto parametric images. Findings were compared with those of 9 normal controls. We found a significant reduction in the mean hypothalamic RAC BP of the PD patients compared with the normal controls (0.2714+/-0.06 vs. 0.3861+/-0.04; mean+/-SD; p=0.0005). ROI results were confirmed with statistical parametric mapping (SPM). Individual hypothalamic BP values of PD patients did not correlate with age, disease duration, disease severity and levodopa equivalent dose. It remains to be ascertained whether the reductions in hypothalamic D(2) receptor availability seen in PD are disease related, the results of chronic exposure to levodopa or both. Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723016     DOI: 10.1016/j.expneurol.2008.07.021

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  34 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

2.  Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic.

Authors:  S Gulyani; R Salas; Z Mari; S Choi; A Mahajan; C Gamaldo
Journal:  Basal Ganglia       Date:  2016-05-27

Review 3.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 4.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

Review 5.  Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Authors:  Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2017-07-12       Impact factor: 3.575

Review 6.  Sleep Disturbance, Cognitive Decline, and Dementia: A Review.

Authors:  Alexandra M V Wennberg; Mark N Wu; Paul B Rosenberg; Adam P Spira
Journal:  Semin Neurol       Date:  2017-08-24       Impact factor: 3.420

Review 7.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

Review 8.  Biomarkers for Parkinson's Disease: Recent Advancement.

Authors:  Sharvari Lotankar; Kedar S Prabhavalkar; Lokesh K Bhatt
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Effects of sleep disorders on the non-motor symptoms of Parkinson disease.

Authors:  Ariel B Neikrug; Jeanne E Maglione; Lianqi Liu; Loki Natarajan; Julie A Avanzino; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel
Journal:  J Clin Sleep Med       Date:  2013-11-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.